On December 16, 2025, Cartesian Therapeutics, Inc. appointed Dr. Adrian Bot as a Class II director, effective until the 2027 annual meeting; he will receive $40,000 annually and stock options worth 17,200 shares with an exercise price of $8.29 per share. The Board also adopted an updated Code of Business Conduct and Ethics on the same date, strengthening ethical standards for all employees.